SCOPE FLUIDICS SA ZY-10 (S84) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SCOPE FLUIDICS SA ZY-10 (S84) has a cash flow conversion efficiency ratio of -0.072x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.68 Million ≈ $-13.65 Million USD) by net assets (€162.43 Million ≈ $189.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of SCOPE FLUIDICS SA ZY-10 to measure how much of total assets are equity-financed.
SCOPE FLUIDICS SA ZY-10 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how SCOPE FLUIDICS SA ZY-10's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SCOPE FLUIDICS SA ZY-10 cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
SCOPE FLUIDICS SA ZY-10 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCOPE FLUIDICS SA ZY-10 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gan Shmuel
TA:GSFI
|
-0.009x |
|
BCP Investment Corp.
NASDAQ:BCIC
|
0.112x |
|
Daemyung Sonoseason Co.Ltd
KQ:007720
|
-0.048x |
|
Shotspotter Inc
NASDAQ:SSTI
|
0.062x |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
0.674x |
|
iCapital.biz Berhad
KLSE:5108
|
0.009x |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
0.017x |
|
Empire State Realty OP LP ES
NYSE:ESBA
|
0.038x |
Annual Cash Flow Conversion Efficiency for SCOPE FLUIDICS SA ZY-10 (2021–2025)
The table below shows the annual cash flow conversion efficiency of SCOPE FLUIDICS SA ZY-10 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see S84 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €162.43 Million ≈ $189.90 Million |
€-46.11 Million ≈ $-53.91 Million |
-0.284x | -65.50% |
| 2024-12-31 | €146.35 Million ≈ $171.10 Million |
€-25.10 Million ≈ $-29.35 Million |
-0.172x | +27.15% |
| 2023-12-31 | €80.93 Million ≈ $94.62 Million |
€-19.06 Million ≈ $-22.28 Million |
-0.235x | -178.45% |
| 2022-12-31 | €332.97 Million ≈ $389.28 Million |
€-28.16 Million ≈ $-32.92 Million |
-0.085x | +97.33% |
| 2021-12-31 | €6.74 Million ≈ $7.88 Million |
€-21.37 Million ≈ $-24.98 Million |
-3.171x | -- |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.